A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia

Journal of Clinical Psychiatry

Volumn 71, Issue 9, 2010, Pages 1226-1233

  Chan, Hung Yu ^a,b,c,d   Chiang, Shu Chuan ^a,e   Chang, Ching Jui ^f,g   Gau, Susan S F ^b   Chen, Jiahn Jyh ^a   Chen, Chiung Hsu ^a   Hwu, Hai Gwo ^b   Lai, Mei Shu ^c  

^a Taoyuan Mental Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CATHAY GENERAL HOSPITAL   (Taiwan)

^g FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CHLORPROMAZINE; CLOPENTHIXOL; FLUPENTIXOL; HALOPERIDOL; LORAZEPAM; LOXAPINE; OLANZAPINE; PIPOTIAZINE; PROPRANOLOL; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZOTEPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AKATHISIA; ARTICLE; BLURRED VISION; CHINESE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEART PALPITATION; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; THIRST; WEAKNESS; BRIEF PSYCHIATRIC RATING SCALE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; FOLLOW UP; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOLOGY; PSYCHOTIC DISORDERS; TAIWAN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TAIWAN;

EID: 77957857043     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05155yel     Document Type: Article

References (56)

1. Glazer WM, Morgenstern H, Doucette JT. The prediction of chronic persistent versus intermittent tardive dyskinesia: a retrospective follow-up study. Br J Psychiatry. 1991;158(6):822-828. doi:10.192/bjp.158.6.82 PubMed
2. Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry. 1996;53(4):313-319. PubMed
3. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35(suppl):S61-S66. doi:10.1016/S0920-964(98)0160-1 PubMed
4. Krausz M, Moritz SH, Naber D, et al. Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia. Eur Psychiatry. 1999;14(2):84-88. doi:10.1016/S0924-938(9)8072-6 PubMed (Pubitemid 36193303)
5. Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol. 1998; 13(suppl 3):S49-S57. doi:10.1097/04850-1980303-09 PubMed
6. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry. 1998;59(suppl 12):17-22. PubMed
7. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425. doi:10.176/api.ajp.161.3.414 PubMed
8. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151-156. doi:10.1097/YCO.0b013e3282f53132 PubMed
9. Emsley RA, Oosthuizen PP, Joubert AF, et al. Treatment of schizophrenia in low-income countries. Int J Neuropsychopharmacol. 1999;2(4): 321-325. doi:10.1017/S1461457901613 PubMed
10. Gau SS, Chung CH, Gau CS. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharmacol. 2008;28(3):271-278. doi:10.1097/JCP. 0b013e3181723713 PubMed
11. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. doi:10.2165/023210-2062050-04 PubMed
12. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994;55(suppl B):102-106. PubMed
13. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158(4):503-510. doi:10.192/bjp.158.4. 503 PubMed
14. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995;15(suppl 1):228-230. doi:10.1097/04714-195060-017
15. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(11):1342-1348. PubMed
16. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5):696-701. PubMed
17. Kinon BJ, Jeste DV, Kollack-Walker S, et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(6):985-996. doi:10.1016/j.pnpbp.204.05.016 PubMed
18. Tenback DE, van Harten PN, Slooff CJ, et al; SOHO Study Group. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005;66(9):1130-1133. PubMed
19. Brar JS, Parepally H, Chalasani L, et al. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population. Ann Clin Psychiatry. 2008;20(3):139-144. PubMed (Pubitemid 352009284)
20. Lykouras L, Agelopoulos E, Tzavellas E. Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(4):815-817. doi:10.1016/S0278-5846(01)0303-7 PubMed
21. O'Brien J, Barber R. Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject. Br J Psychiatry. 1998; 172(2):186. doi:10.192/bjp.172.2.186a PubMed
22. Littrell KH, Johnson CG, Littrell S, et al. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry. 1998;55(3):279-280. doi:10.101/archpsyc.5.3.279 PubMed (Pubitemid 28128617)
23. Almeida OP. Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry. 1998;59(7):380-381. PubMed
24. Sacchetti E, Valsecchi P. Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int Clin Psychopharmacol. 2003;18(6):357-359. doi:10.1097/04850-20310-08 PubMed
25. Kantrowitz JT, Srihari VH, Tek C. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol. 2007;27(5):525-526. doi:10.1097/JCP.0b013e31814f302 PubMed
26. Peritogiannis V, Tsouli S, Zafiris S, et al. Improvement of tardive dyskinesia following amisulpride treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):748-750. doi:10.1016/j.pnpbp.206.01.02 PubMed
27. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38. PubMed
28. Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997;16(2):93-110, discussion 111-135. doi:10.1016/S0893-13X(96)0187-X PubMed
29. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3(2):123-134. doi:10.1038/sj.mp.4036 PubMed
30. Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry. 1997;58(suppl 10):28-36. PubMed
31. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2):57-73. doi:10.107/BF0245606 PubMed
32. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2-3):247-265. doi:10.1016/j.schres.205.02. 013 PubMed (Pubitemid 40804771)
33. Bech P, Larsen JK, Andersen J. The BPRS: psychometric developments. Psychopharmacol Bull. 1988;24(1):118-121. PubMed
34. Clinical Global Impression (CGI). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976;218-222.
35. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39(11):1172-1177. PubMed
36. Liu CY, Chiu NY, Wu CK, et al. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int Clin Psychopharmacol. 2003;18(1):49-51. doi:10.1097/04850-203010-08 PubMed
37. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):1-56. PubMed
38. Bai YM, Yu SC, Chen JY, et al. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol. 2005;20(2):79-85. doi:10.1097/04850-205030-03 PubMed
39. Chen JJ, Chan HY, Sun HJ, et al. Response to olanzapine for a patient with tardive dyskinesia. Taiwanese J Psychiatry. 2002;16:163-168.
40. Chan HY, Chang CJ, Chiang SC, et al. A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism. J Psychopharmacol. 2010;24(1):91-98. doi:10.17/02698108096070 PubMed
41. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006;20(4):293-301. doi:10.2165/023210-2062040-03 PubMed
42. Greil W, Haag H, Rossnagl G, et al. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study. Br J Psychiatry. 1984; 145(3):304-310. doi:10.192/bjp.145.3.304 PubMed
43. Bergman J, Dwolatzky T, Brettholz I, et al. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry. 2005;66(1):107-110. PubMed
44. Soares KV, McGrath JJ. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2): CD000204. PubMed
45. Tammenmaa IA, McGrath JJ, Sailas E, et al. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2002;(3):CD000207. PubMed
46. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156(2):286-293. PubMed
47. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics, Pt 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541-547. PubMed (Pubitemid 43161786)
48. Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry. 1991;148(1):85-89. PubMed
49. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. 2004;38(6):445-449. PubMed
50. Sundram S, Lambert T, Piskulic D. Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;117(6):474-478. doi:10.1/j.160-047.208.0183.x PubMed
51. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157(7):1150-1155. doi:10.176/api.ajp.157.7.150 PubMed
52. Chen JY, Bai YM, Pyng LY, et al. Risperidone for tardive dyskinesia. Am J Psychiatry. 2001;158(11):1931-1932. doi:10.176/api.ajp.158.1.1931 PubMed
53. Bhanji NH, Margolese HC. Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia. Can J Psychiatry. 2004;49(5):343. PubMed
54. Ananth J, Kenan J. Tardive dyskinesia associated with olanzapine monotherapy. J Clin Psychiatry. 1999;60(12):870. PubMed
55. Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. J Clin Psychiatry. 1985;46(8, Pt 2):4-7. PubMed
56. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158(3):360-369.